Visterra’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Visterra develops and commercializes antibody therapeutics for the treatment of pandemic influenza and chronic kidney diseases. Read more

9 Followers on Owler
9 Followers on Owler
9 Followers on Owler
9 Followers on Owler

Visterra develops and commercializes antibody therapeutics for the treatment of pandemic influenza and chronic kidney diseases. Read more

Brian Pereira's photo - President & CEO of Visterra

President & CEO

Brian Pereira

CEO Approval Rating

89/100

Founded:

2007

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Immune Design is one of Visterra's top rivals. Immune Design's headquarters is in Seattle, Washington, and was founded in 2008. Like Visterra, Immune Design also competes in the Pharmaceuticals industry. Immune Design generates 73% of Visterra's revenue.

Aileron Therapeutics Inc has been one of Visterra's top competitors. Aileron Therapeutics Inc was founded in 2005 in Watertown, Massachusetts. Aileron Therapeutics Inc operates in the Health Care Services industry. Aileron Therapeutics Inc generates $1M more revenue than Visterra.

Arsanis is one of Visterra's top competitors. Arsanis was founded in Waltham, Massachusetts} in 2010. Like Visterra, Arsanis also works within the Biotechnology field. Compared to Visterra, Arsanis generates $2M less revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Chimerix, Inc. a competitor of Visterra?

Acquisitions

No recent acquisitions found related to Visterra

Visterra Funding History

$3.2M$9.2M$56.4M$64.5M$94.5M$117.6M$141.2M

Since Visterra was founded in 2007, it has participated in 8 rounds of funding. In total Visterra has raised $141.2M. Visterra's last funding round was on Oct 2017 for a total of $23.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series C
Oct 2017
$23.6M
Series C
May 2016
$23.1M
-
Series B
Oct 2014
$30M
Series A
Dec 2013
$8.1M
Series A
Nov 2012
$13M

Since Visterra was founded in 2007, it has participated in 8 rounds of funding. In total Visterra has raised $141.2M. Visterra's last funding round was on Oct 2017 for a total of $23.6M

Investments

No recent investments found related to Visterra

Visterra News

October 1, 2018BioPortfolio

Visterra Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24072018 Prices from USD $250

SummaryVisterra Inc Visterra formerly Parasol Therapeutics Inc is a clinicalstage biopharmaceutical c... See more »
September 4, 2018PE Hub Network

Otsuka completes Visterra acquisition for about $430 mln

Otsuka has closed its previously announced acquisition of Visterra, a developer of antibody-based the... See more »
September 1, 2018BioPortfolio

Visterra Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 20062018 Prices from USD $250

SummaryVisterra Inc Visterra formerly Parasol Therapeutics Inc is a clinicalstage biopharmaceutical c... See more »
July 16, 2018PharmaTech

Otsuka to Acquire Visterra for $430 Million

On July 11, 2018, Otsuka Pharmaceutical, a subsidiary of Otsuka Holdings, and Visterra, a clinical-st... See more »
March 7, 2018PharmiWeb

Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory Pathogens

Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Re... See more »
February 5, 2018The Business Journals

Cambridge biotech Visterra moving HQ to Waltham

A Visterra spokesperson said the new space is almost double the size of the company's current headqua... See more »

Visterra Press Releases

September 9, 2015BUSINESS WIRE

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)--Visterra, Inc. and Serum Institute of India Ltd. hav... See more »
September 2, 2015BUSINESS WIRE

Visterra Announces Appointment of John Weidenbruch as General Counsel

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., announced that it has appointed John Weidenbruch a... See more »
August 18, 2015BUSINESS WIRE

Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra announced that new preclinical results for VIS410, monocl... See more »
July 16, 2015BUSINESS WIRE

Visterra Announces Publication in the Journal Cell, Demonstrating That Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes of Dengue Virus in Preclinical Studies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra Announces Publication in the Journal Cell, Demonstrating ... See more »
June 2, 2015BUSINESS WIRE

Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra Announces Presentation of Data at International Influenza... See more »
May 26, 2015PR-INSIDE.COM

New market study, "Visterra, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile", has been published

(PR-inside.com) Visterra, Inc. (Visterra), formerly Parasol Therapeutics, Inc., is a biotechnology co... See more »

Visterra Videos

Social Media

Headquarters

275 2nd Avenue

Waltham, Massachusetts02451

617-498-1070

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Visterra develops and commercializes antibody therapeutics for the treatment of pandemic influenza and chronic kidney diseases. Visterra was founded in 2007. Visterra's headquarters is located in Waltham, Massachusetts, USA 02451. It has raised 141.2M...

CEO

Visterra's President & CEO, Brian Pereira, currently has an approval rating of 89%. Visterra's primary competitors are Immune Design, Aileron Therapeutics Inc & Arsanis.

Website

visterrainc.com

Frequently Asked Questions about Visterra

  1. When was Visterra founded?

    Visterra was founded in 2007
  2. Who is Visterra's CEO?

    Visterra's CEO is Brian Pereira
  3. How much revenue does Visterra generate?

    Visterra generates $3M in revenue
  4. How much funding does Visterra have?

    Visterra has historically raised $141.2M in funding
  1. Where is Visterra's headquarters?

    Visterra's headquarters is in Waltham Massachusetts, USA
  2. How many employees does Visterra have?

    Visterra has 70 employees
  3. What sector does Visterra operate in?

    Visterra is in Pharmaceuticals, Biotechnology
  4. Who are Visterra's competitors?

    Visterra's top competitors are Immune Design, Aileron Therapeutics Inc, Arsanis